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90Vitamin D deficiency is common in Crohn’s disease (CD). High-dose vitamin D had anti-
inflammatory effects in preclinical studies and trials of patients with CD. We performed a
randomized trial to determine whether high-dose vitamin D prevents postoperative recurrence








100Patients with CD after ileocolonic resection with ileocolonic anastomosis were assigned
randomly to groups given weekly 25,000 IU oral vitamin D (n [ 72) or placebo (n [ 71) for 26
weeks, at 17 hospitals in The Netherlands and Belgium, from February 2014 through June 2017.
Patients were assessed at baseline and at weeks 2, 6, 12, and 26 for laboratory and clinical
parameters, and underwent ileocolonoscopy at 26 weeks. The primary end point was endo-
scopic recurrence (modified Rutgeerts score, ‡i2b, as assessed by blinded readers) at 26 weeks.
Secondary end points included clinical recurrence (Crohn’s disease activity index, ‡220),
quality of life (measured by the 36-Item Short Form Health Survey, Inflammatory Bowel Disease
Questionnaire, and EuroQol, a 5-dimension questionnaire), and outcomes associated with the







109In the vitamin D group, serum levels of 25-hydroxy vitamin D increased from a median of 42
nmol/L at baseline to 81 nmol/L at week 26 (P < .00001), whereas levels did not change
significantly in the placebo group and remained unchanged at 43 nmol/L. In the intention-to-
treat analysis, the proportion of patients with endoscopic recurrence at 26 weeks did not
differ significantly between the vitamin D vs the placebo group (58% vs 66%; P [ .37). The
cumulative rate of clinical recurrence did not differ significantly between the groups (18.1% in
the vitamin D group vs 18.3% in the placebo group; P [ .91). Quality of life improved slightly
over time in both groups, but did not differ significantly between groups (P [ .07). There were
few adverse events in either group.r: 25-OH vitamin D, 25-hydroxy vitamin D;
rohn’s Disease Activity Index; CRP, C-
atory bowel disease; IQR, interquartile
amin D receptor.
© 2020 by the AGA Institute. Published by Elsevier, Inc. This is an open













































































177High-dose vitamin D, compared with placebo, did not reduce the incidence of postoperative
endoscopic or clinical recurrence of CD in patients who underwent ileocolonic resection with










































222The majority of patients suffering from Crohn’sdisease (CD) and other immune-mediated dis-
eases have low serum concentrations of 25-hydroxy
vitamin D (25-OH vitamin D).1–4 National guidelines
differ significantly on normal serum concentrations.
Vitamin D has anti-inflammatory and antifibrotic proper-
ties in the gut.5–7
Calcitriol, the active form of vitamin D, down-
regulates several proinflammatory cytokines.8–10
Furthermore, in vitamin D–deficient interleukin 10
knockout mice, diarrhea and wasting improved signifi-
cantly after 2 weeks of vitamin D treatment.11
Binding of calcitriol to the vitamin D receptor (VDR)
stimulates transcription of vitamin D–responsive genes.
VDR expression is down-regulated considerably in in-
flammatory bowel disease (IBD) patients regardless of
inflammation, compared with healthy controls.12
Furthermore, a murine VDR knockout model is more
susceptible to experimental colitis.13
In CD patients, serum 25-OH vitamin D levels less than
50 nmol/L have been associated with an increased risk of
surgery compared with levels greater than 75 nmol/L.14
One prospective trial with 104 patients randomized 1:1
to receive vitamin D3 or placebo showed that the clinical
relapse rate of CD patients in medical remission was
lower in patients treated with daily 1200 IU vitamin D
compared with placebo (13% vs 29%).15 Endoscopy was
not performed in this trial and clinical outcomes just failed
to reach statistical significance (P ¼ .06).
CD recurs in 50% to 80% of patients after ileocolonic
within 6 to 12 months.16,17 Because the majority of CD
patients require surgery during their disease course,18 it
is important to develop therapeutic interventions that
alter the ‘natural course’ of CD recurrence. To date,
medical treatments to prevent recurrence have had
limited success.19–23
Because vitamin D has potential disease-modulating
effects and it is safe and inexpensive, we investigated
the anti-inflammatory effect of high-dose oral vitamin D
on the recurrence of postoperative CD in a placebo-











Patients undergoing ileocecal or ileocolonic resection
with ileocolonic anastomosis for CD were recruited
across 17 regional and academic hospitals in The
Netherlands and Belgium between February 2014 andFLA 5.6.0 DTD  YJCGH57247_proof June 2017. The Institutional Board and Medical Ethical
Committee at each site approved the trial, and patients
provided written informed consent.
Patients had established ileal or ileocolonic CD, were
18 years of age or older, and underwent a first or second
ileocecal or ileocolonic resection with ileocolonic anasto-
mosis or had closure of a loop ileostomy after a previous
ileocecal or ileocolonic resection. Patients with normal
serum calcium levels not exceeding the upper limit of
normal were enrolled within 14 days after surgery.
Exclusion criteria included the presence of macro-
scopic evidence for CD at the proximal or distal resection
margin. Patients with an ileorectal anastomosis or active
perianal fistulae were excluded. Patients with an exten-
sive small-bowel resection (>60 cm small bowel
removed), additional stricturoplasty or other small-
bowel resections, a postoperative definite stoma, pri-
mary hyperparathyroidism, sarcoidosis or tuberculosis,
and pregnant/breastfeeding patients were ineligible.
Postoperatively, all CD medication was stopped except
for ongoing steroids, which were tapered gradually in the
weeks after surgery according to local guidelines. No
multivitamin or open-label vitamin D preparations were
allowed during the study period and patients were not
allowed to use tanning beds.Study Design
Patients were randomized 1:1 to receive weekly
25,000 IU of vitamin D3 (cholecalciferol in 1-mL oral
vials, D-Cura; Laboratoires SMB, Brussels, Belgium) or
comparable placebo vials (Laboratoires SMB). Randomi-
zation was performed at the pharmacy of the Amsterdam
University Medical Center within 2 weeks after surgery,
and subjects were stratified by baseline 25-OH vitamin D
level (<75 or 75 nmol/L).24 Patients, attending physi-
cians, and all other study personnel were blinded to the
treatment regimen and laboratory results. Cholestyr-
amine and/or loperamide were allowed for the treat-
ment of bile acid diarrhea. In that case, patients were
instructed to take the study drug at least 6 hours after
the intake of cholestyramine to prevent interaction. The
vitamin D dosage was selected based on the balance
between potential benefits and risks, taking into account
previously published data.15,25,26
Patients were assessed at baseline and at weeks 2, 6,
12, and 26 after randomization. Laboratory assessment
included hematology, liver, and kidney function tests, as
well as C-reactive protein (CRP), serum albumin, 25-OH
vitamin D, calcium and parathyroid hormone, and fecal26 July 2020  4:55 am  ce DVC
What You Need to Know
Background
Vitamin D deficiency is common in patients with
Crohn’s disease (CD). Some studies have reported
anti-inflammatory effects of vitamin D in models of
or patients with CD.
Findings
Weekly 25,000 IU of vitamin D doubled serum 25-
hydroxy vitamin D levels in patients randomized to
vitamin D after 6 weeks of treatment and remained
stable thereafter. However, there was no difference
in the incidence of endoscopic or clinical recurrence
at week 26 in the vitamin D vs the placebo groups.
Outcome was not affected by baseline serum vitamin
D level, season of inclusion, or ethnicity.
Implications for patient care
Oral high-dose vitamin D (25,000 IU) weekly is well
tolerated and normalizes serum concentrations in
patients with CD. However, it does not prevent
postoperative recurrence of CD after ileocolonic
resection.




















































































































348calprotectin levels. Determination of 25-OH vitamin D
was performed using the chemiluminescent immuno-
assay technology (Liaison; DiaSorin, Stillwater, MN). The
Crohn’s Disease Activity Index (CDAI) was measured at
each visit based on 7-day scoring by the patient before
this visit.27 Moreover, quality-of-life questionnaires were
administered at each visit: the EuroQol, a 5-dimension
questionnaire, the 36-Item Short Form Health Survey,
and the Inflammatory Bowel Disease Questionnaire.28–30
At week 26, an ileocolonoscopy was performed. Central
readers scored the ileocolonoscopy for the modified
Rutgeerts score.31
All authors had access to the study data and reviewed
and approved the final manuscript.
End Points
The primary end point was the proportion of patients
with significant endoscopic recurrence in the neo-
terminal ileum 6 months after surgery, defined as a
modified Rutgeerts score of i2b or higher.31
Secondary end points included endoscopic recur-
rence at week 26, defined as a Rutgeerts score of i2a or
higher and i1 or higher, the proportion of patients with
clinical recurrence (CDAI, 220) at any time during
follow-up evaluation, differences in recurrence among all
patients with low 25-OH vitamin D levels at baseline,
quality of life as measured by each of the questionnaires,
and adverse events.
Patients who developed symptoms of CD recurrence
earlier than 6 months after surgery underwent fecal cal-
protectin and CRP testing. If the fecal calprotectin con-
centration was 250 mg/g or greater and the CRP was 5
mg/L or greater, patients underwent an earlier ileocolo-
noscopy. If this procedure was fewer than 6 weeks before
the primary end point, the endoscopic score was used for
the primary end point (last observation carried forward).
If the ileocolonoscopy was more than 6 weeks before the
primary end point and showed recurrence (Rutgeerts
score of i2b by the local investigator), the patient was
considered to have failed treatment and received alter-
native treatment at the discretion of the local investigator.
Central Reading of Endoscopies
All videotapes of the ileocolonoscopies were blinded
and scored independently at the end of the trial by 2
experienced IBD endoscopists (G.D. and P.B.). The videos
with disagreement in scoring were reviewed during a
second round by the 2 readers together during an
adjudication meeting, after which the agreed score was
used for analysis.
Sample Size Calculation and Statistical Analysis
As a basis for sample size calculation, we reviewed the
endoscopic recurrence rates of CD patients after ileocolonicFLA 5.6.0 DTD  YJCGH57247_proof resection with anastomosis at the Amsterdam University
Medical Center between 2007 and 2013 who had not
received postoperative CD therapy (n¼ 105). Of these, 55%
had significant endoscopic recurrence (i2b) after 6 to 12
months.32 Based on this we estimated the rate of endo-
scopic recurrence on placebo to be 55%. At the time the
study was designed, 1 randomized placebo-controlled trial
with vitamin D in CD was published using clinical relapse as
the primary end point.15 Risk reduction of relapse with
vitamin D in this trial was 45%. We decided to power the
trial for an absolute effect size of 25% for significantly less
endoscopic recurrence in the vitamin D group.
To attain a power of at least 80% in a 2-sided test
model with an a error of less than .05, inclusion of 61
patients in each group was necessary. With an estimated
loss to follow-up evaluation of 15%, the target sample size
was 144. Endoscopic recurrence rates were analyzed by
the Pearson chi-square test. The time to clinical recur-
rence was analyzed using Kaplan–Meier curves and the
log-rank test. The association between recurrence and
risk factors of recurrence was analyzed using logistic
regression. Logistic regression also was used to evaluate
whether the vitamin D treatment effect on recurrence rate
differed between subgroups of patients. Change of quality
of life was analyzed using linear mixed-effect regression
models with time and treatment as fixed factors. The
interaction test between time and treatment was used to
test the null hypothesis that the averaged change patterns
in the 2 treatment groups did not differ. In addition, we
compared the averaged quality-of-life levels at 26 weeks,
estimated from the mixed-effects models. The effect of
























































































































464laboratory parameters were analyzed with similar linear
mixed-effects regression models, after logarithmic trans-
formation for some parameters to improve goodness-of-
fit to the mixed-effects regression models. Drop-out and
adverse event rates were compared between the 2 treat-
ment groups with the Pearson chi-square test. A P value of
.05 or less was used to indicate a statistically significant
difference. Both an intention-to-treat analysis (in patients
receiving at least 1 dose of trial medication) and a per-
protocol analysis were performed.
Results
Demographic and Baseline Disease
Characteristics
In total, 143 patients were randomized, of whom 72
patients received vitamin D and 71 patients received
placebo. Patient characteristics are shown in Table 1.
Fifty-seven men and 86 women were included, with a
median age of 32 years (interquartile range [IQR], 25–43
y). Twenty-five patients had an inflammatory disease
phenotype, 75 patients had stricturing disease, and 36
patients had a penetrating phenotype as based on the
Montreal classification at the time of surgery.33 Twenty-
nine patients underwent previous surgical resections.
The 2 groups were well balanced with respect to de-
mographic and disease characteristics (Table 1) (all data
nonsignificantly different).
In the placebo group, all but 1 patient received at
least 1 dose of trial medication (Supplementary
Figure 1). Hence, the entire intention-to-treat popula-
tion consisted of 72 patients randomized to vitamin D
and 70 patients to placebo. Because not all patients un-
derwent the week 26 endoscopy, we analyzed a modified
intention-to-treat population of patients who underwent
colonoscopy, consisting of 63 patients on vitamin D and
55 on placebo. In both groups, 3 patients discontinued
trial medication before month 6 because of clinical dis-
ease exacerbation, of whom 2 patients in the placebo
group needed repeat surgery. The other 4 patients with
early clinical relapse underwent colonoscopy and this
score was used for the primary end point. In total, 58
patients completed the full study in the vitamin D group
and 54 patients in the placebo group (per-protocol
population). Three patients discontinued treatment for
adverse events (2 in the vitamin D group, and 1 in the
placebo group). The total drop-out rate was 18.2% (26 of
143). Drop-out rates did not differ significantly between
both groups (13 of 72 vs 13 of 71; P ¼ .999).
Treatment Effect on Serum 25-Hydroxy Vitamin
D Levels
The 25-OH vitamin D serum median concentrations at
baseline were 42 nmol/L (IQR, 10–119 nmol/L) and 43
nmol/L (IQR, 7–108 nmol/L) for patients on vitamin DFLA 5.6.0 DTD  YJCGH57247_proof treatment and placebo, respectively (Figure 1). There
was a clear and highly significantly different change
pattern of 25-OH vitamin D levels between the 2 treat-
ment groups (P < .00001). 25-OH vitamin D concentra-
tions were stable in the placebo group throughout the
duration of the trial (average change, 3 nmol/L; SE, 4;
P ¼ .74) and increased significantly by an average of 40
nmol/L (SE, 5; P < .00001) by week 6 in the vitamin D
treatment group, further remaining at this increased
level for the remaining duration of the trial. This effect
represented an increase of 101% (95% CI, 72%–135%)
of the median 25-OH vitamin D levels. Concomitant
cholestyramine had no effect on median serum 25-OH
vitamin D levels.
The effect of vitamin D treatment on other biochem-
ical parameters is shown in Supplementary Table 1.
There were no significantly different change patterns
between the 2 treatment groups, except for parathyroid
hormone levels that increased slightly more in patients
treated with placebo (from slightly lower baseline
levels). Fecal calprotectin levels decreased between
baseline and week 6 in the placebo group, but increased
slightly thereafter and were not significantly different at
week 26.Endoscopic Recurrence
Table 2 summarizes the consensus scoring of the
endoscopic findings.
For the primary outcome analysis of endoscopic
recurrence, all patients who discontinued the trial before
week 26 without having an endoscopy were considered
to have failed the treatment (Rutgeerts score, i2b). In
this pure intention-to-treat population, 42 of 72 (58%)
patients in the vitamin D group vs 46 of 70 (66%) in the
placebo group had endoscopic recurrence (odds ratio
[OR]; 95% CI; P ¼ .37) (Figure 2A).
In the modified intention-to-treat population (pa-
tients with week 26 endoscopy), 33 of 63 (52%) patients
had a Rutgeerts score of i2b or higher in the vitamin D
group, and 31 of 55 (56%) in the placebo group (P ¼ .71)
(Figure 2B). With a different cut-off value for recurrence
of Rutgeerts score of i2a or higher, recurrence rates were
87% vs 82% in the vitamin D and placebo groups,
respectively (P ¼ .45), and with a Rutgeerts score of i1 or
higher recurrence rates were 94% and 86%, respectively
(P ¼ .22). Comparing the distribution of all 63 and 55
patients over the 6 endoscopic recurrence categories, the
P value was .61.
In the per-protocol analysis, there were 29 of 58
(50%) patients with a Rutgeerts score of i2b or higher in
the vitamin D group and 31 of 54 (57%) in the placebo
group (P ¼ .43). A Rutgeerts score of i2a or higher
recurrence rates were 86% vs 82% in the vitamin D and
placebo groups, respectively (P ¼ .50), and by defining a
Rutgeerts score of i1 or higher the recurrence rates were




Table 1. Demographic and Baseline Disease Characteristics






Sex, male, n (%) 28/72 (39) 29/71 (41)
Age, y, median (IQR) 31 (25–46) 33 (25–46)
Age >40 y, n (%) 17/72 (24) 26/71 (36)
Ethnic background, Caucasian, n
(%)
68/72 (94) 57/71 (79)
Behavioral risk factors
Current smoker, n (%) 13/70 (19) 13/67 (19)
BMI, kg/m2, mean (SD) 23.7 (4.8) 23.0 (4.6)
Disease characteristics
Age at diagnosis, n (%)
16 y, A1 9/72 (13) 12/71 (17)
17–40 y, A2 57/72 (79) 45/71 (64)
>40 y, A3 6/72 (8) 13/71 (18)
Disease location at surgery, n (%)
Ileum only, L1 28/72 (39) 39/71 (56)
Colon only, L2 1/72 (1) 2/71 (3)
Ileum and colon, L3 43/72 (60) 29/71 (41)
Disease phenotype at surgery, n (%)
Inflammatory, B1 11/72 (15) 17/71 (24)
Stricturing, B2 40/72 (56) 36/71 (51)
Penetrating, B3 21/72 (29) 17/71 (24)
Perianal disease, p 0/72 (0) 0/71 (0)
Previous surgical resections 17/72 (24) 14/70 (20)
CDAI at study entry, median
(minimum–maximum)
165 (19–394) 136 (1–463)
CDAI, 150–199, n (%) 13/54 (24) 8/53 (15)
CDAI, 200–219, n (%) 1/54 (2) 2/53 (4)
CDAI, 220, n (%) 17/54 (31) 14/53 (26)
Steroid use
Prednisone 45/71 (63) 43/67 (64)
Budesonide 35/71 (49) 34/67 (51)
MesalamineQ23 22/71 (31) 17/67 (25)
Immunomodulators, n (%)
Azathioprine 47/71 (66) 40/67 (59)
6-Mercaptopurine 13/71 (18) 20/67 (30)
Methotrexate 8/71 (11) 6/67 (9)
Previous anti-TNFa, n (%)
Infliximab 12/71 (17) 21/67 (31)
Adalimumab 13/71 (18) 11/67 (16)
Any anti-TNF 19/71 (27) 10/67 (15)
Biochemical parameters, median
(minimum–maximum)
CRP, mg/L 37 (1–251) 34 (1–318)
25-OH vitamin D, nmol/L, n (%) 42 (10–119) 43 (7–108)
25 nmol/L 15/67 (22) 12/63 (19)
26–50 nmol/L 30/67 (45) 27/63 (43)
51–74 nmol/L 11/67 (16) 17/63 (27)
75 nmol/L 11/67 (16) 7/63 (11)
Serum albumin, g/L, median
(minimum–maximum)
36 (23–51) 37 (19–46)
BMI, body mass index; CDAI, Crohn’s disease activity index; CRP, C-reactive
protein; IQR, interquartile range; 6-MP, 6-mercaptopurine; TNFa, tumor ne-
crosis factor a; 25-OH vitamin D, 25-hydroxy vitamin D.

















































































































577distribution of all 58 and 54 patients over the 6 Rut-
geerts categories, the P value was .52.FLA 5.6.0 DTD  YJCGH57247_proof Clinical Recurrence
The incidence of clinical recurrence, measured with
CDAI scores, is summarized in Supplementary Table 2
and Figure 2C. There was no significant difference be-
tween the 2 treatment groups with respect to the dis-
tribution of the patient numbers over the CDAI
categories (P > .065) at any time point.Risk Factors for Endoscopic Recurrence
The ORs of ‘established’ risk factors for endoscopic
recurrence are listed in Table 3. Previous surgery was
associated with a lower risk of endoscopic recurrence
(OR, 0.35; 95% CI, 0.15–1.00; P ¼ .049). Current smoking
was associated with a higher risk of recurrence but just
did not reach significance (OR, 3.1; 95% CI, 0.98–9.67;
P ¼ .054). Higher 25-OH vitamin D levels (>50 nmol/L)
at baseline were associated numerically with a lower
recurrence risk, but this trend also failed to reach sig-
nificance (P ¼ .3). Moreover, there was no difference in
endoscopic recurrence based on an increase of vitamin D
levels from pretreatment to post-treatment. Patients
with endoscopic recurrence (Rutgeerts score, i2b) had
a significantly higher calprotectin level at week 26 than
patients with a Rutgeerts score of i2a or less (mean, 448
mg/g; SD, 354; vs 236 mg/g; SD, 265; P ¼ .002). More-
over, patients with an increased CRP level (>5 mg/L) at
week 26 had endoscopic recurrence more often
compared with patients with normal CRP levels (75% vs
49%; OR, 1.15; P ¼ .019).Quality of Life
Quality of life was measured by changes in the
EuroQol, a 5-dimension questionnaire, the SF-36, and the
Inflammatory Bowel Disease Questionnaire during the
trial. In general, the scores of all questionnaires
improved slightly during the trial, but at none of the
visits was there a statistically significant difference be-
tween the vitamin D and placebo groups (P > .07)
(Supplementary Table 3).Subgroups
The treatment effect on endoscopic and clinical
recurrence was analyzed by subgroups of patients
defined by baseline 25-OH vitamin D levels, low baseline
calcium levels, low baseline parathyroid hormone levels,
calprotectin at week 26, ethnic background, and season
of inclusion (autumn/winter). Treatment effects are
shown in Supplementary Figure 2. No differential effect




Figure 1. Treatment effect
on 25-hydroxyvitamin D
serum concentrations. The
observed serum vitamin D
levels for all patients are
shown (dark lines repre-
sent the patients in the
vitamin D group, light
lines represent the pa-
tients in the placebo
group). The bold lines
indicate the estimated
mean levels from the
mixed-effects regression
model with time as a factor
(0, 6, 12, and 26 wk) and
treatment and their inter-
action as fixed effects and
a random intercept and
slope of time as random
patient effects. The dotted
lines indicate the esti-
mated 95% CIs of the
estimated regression lines.
The reported P value is for
the interaction term of time
with treatment. OH vitamin















Table 2. Endoscopic Findings of All Available Colonoscopies,
Central Adjudicated Reading
Outcome Vitamin D Placebo
Intention-to-treat analysis n ¼ 72 (%) n ¼ 70 (%)
i0 4 (5.6) 8 (11.4)
i1 4 (5.6) 2 (2.9)
i2a 22 (27.7) 14 (20)
i2b 22 (27.7) 20 (28.9)
i3 2 (2.8) 3 (4.3)
i4 9 (12.5) 8 (11.4)
Modified intention-to-treat analysis n ¼ 63 (%) n ¼ 55 (%)
i0 4 (6.3) 8 (14.5)
i1 4 (6.3) 2 (3.6)
i2a 22 (34.9) 14 (25.5 )
i2b 22 (34.) 20 (36.4)
i3 2 (3.2 ) 3 (5.5)
i4 9 (14.3) 8 (14.5)
Per-protocol analysis n ¼ 58 (%) n ¼ 54 (%)
i0 4 (6.9) 7 (13.0)
i1 4 (6.9) 3 (5.6)
i2a 21 (36.2) 13 (24.0)
i2b 21 (36.2) 20 (37.0)
i3 1 (1.7) 3 (5.6)
i4 7 (12.1) 8 (14.8)
NOTE. Results of the primary intention-to-treat analysis concerned the modi-
fied intention-to-treat analysis.
FLA 5.6.0 DTD  YJCGH57247_proof 










































































































In total, 337 adverse events were reported, 182 in the
vitamin D group and 155 in the placebo group. The pro-
portion of patients reporting 1 or more adverse events
was 59 (82%) and 53 (74%) for the vitamin D and pla-
cebo groups, respectively (P ¼ .32). Twenty-five percent
of all adverse events were related to surgery. Thirty-eight
were reported as serious adverse events (15 patients
receiving vitamin D and 23 patients receiving placebo).
One patient receiving placebo was diagnosed with colonic
adenocarcinoma, all other events were related to hospi-
talization. No deaths occurred. Most adverse events were











In this study we investigated the effect of high-dose
vitamin D treatment to prevent postoperative recur-
rence of CD after an ileocolonic resection with ileocolonic
anastomosis. Vitamin D at a dose of 25,000 IU/wk orally
did not reduce endoscopic or clinical recurrence
compared with placebo, despite doubling of the serum

















Figure 2. Endoscopic and clinical recurrence. (A) Percentage of patients with endoscopic recurrence at 26 weeks, defined as a
Rutgeerts score of i2b or greater in the intention-to-treat analysis (58% vs 66%; P ¼ .37). (B) Percentage of patients with
endoscopic recurrence at 26 weeks, defined as a Rutgeerts score of i2b or greater in the modified intention-to-treat analysis
(52% vs 56%; P ¼ .71). (C) Percentage of patients with clinical recurrence at any time point during follow-up evaluation,
defined as a Crohn’s disease activity index (CDAI) score of 220 or higher (18% vs 18%; P ¼ .93).




















































































































812There is an ongoing debate whether vitamin D defi-
ciency in CD is a cause for or consequence of active
disease because vitamin D deficiency is common in CD
patients. Interventional trials with vitamin D have, to
date, not provided conclusive answers to this enigma.
One of the weaknesses has been the exclusive use of
symptom-based end points, which is known to be asso-
ciated poorly with objective evidence of inflammation.34
Two prospective trials in IBD patients receiving vitamin
D evaluated clinically significant relapse based on CDAI
scores, serum CRP level, and/or quality of life15,35,36 and
observed fewer relapses in patients treated with vitamin
D. However, in another small clinical trial in CD patients
in remission, there was no difference in clinical remis-
sion rates.37 In our study, we decided to use a more
robust end point (blinded centrally read endoscopic
recurrence) as an outcome measure in an established
clinical model in which other interventions were shown
to be beneficial.
Because the endoscopic appearance 6 months after
surgery is a predictor of the clinical disease course,
follow-up evaluation of studies on postoperative recur-
rence often do not exceed 6 months. With a clinical end
point longer follow-up evaluation may be recommended,
as it was performed in the PREVENT trial.17 The inci-
dence of endoscopic recurrence that we observed in the
current trial (56%) was comparable with that in other
studies.17,19,22 Hence, the population in our trial can be
considered as representative.
In our risk factor analysis we observed that current
smoking was associated with a higher, although not
significant, risk for postoperative recurrence, which is in
line with previous studies.38 Conversely, previous sur-
gery was associated with a lower risk for endoscopic
recurrence. A possible explanation could be that patients
with active perianal fistulas were excluded from this
study, and patients with perianal disease phenotype
usually have higher recurrence rates.39 In addition, the
indication for which patients undergo a first resection
may have changed over the years. Current treatmentFLA 5.6.0 DTD  YJCGH57247_proof algorithms now have positioned limited ileocecal resec-
tion as a valid alternative for biologic treatment after
failure of immunomodulators, predominantly in patients
with fibrostenotic disease,40,41 and patients with this
disease phenotype typically have lower recurrence
rates.42
There is an ongoing debate about the minimal or
optimal serum concentration of 25-OH vitamin D in
normal individuals and in patients with chronic inflam-
matory diseases. Reference levels, however, are based
mainly on the skeletal effects of vitamin D, whereas the
effect of vitamin D on extraskeletal functions remains
uncertain. Levels higher than 75 nmol/L are considered
to be necessary for immunomodulatory and nonskeletal
effects,43 although certain investigators have suggested
levels greater than 100 nmol/L may be needed.44
Because the patients on vitamin D in our study reached
serum concentration levels greater than 75 nmol/L, we
believe that they received sufficient doses to benefit from
an anti-inflammatory effect should there be any. None of
our vitamin D–treated patients developed hypercalcemia,
so the weekly dose of 25,000 IU vitamin D also can be
considered safe. Furthermore, seasonal variations of
serum concentration of 25-OH vitamin D are significant
in Western populations.45 Because we included patients
over a time period of 3 years with a stable inclusion rate
through all seasons, seasonal influence was minimalized.
Moreover, the season in which a patient was included
had no effect on endoscopic recurrence.
The current study was a multicenter, double-blind,
randomized, placebo-controlled, clinical trial. The pa-
tient cohort was well characterized and monitored
closely. We studied CD activity during treatment with
vitamin D using endoscopy. Given all of these factors, we
could not observe any anti-inflammatory effect with this
regimen in postoperative CD.
Our study had a few limitations that probably did not
have an impact on the final results. First, we observed a
higher drop-out rate than anticipated (18.2%). The
higher loss to follow-up evaluation rate could be owing26 July 2020  4:55 am  ce DVC
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16 y, A1 1.00 – –
17–40 y, A2 2.32 0.78 6.83
>40 y, A3 3.67 0.85 15.84
Number of previous surgical
resections
1 0.38 0.15 1.00
Smoking
Current smoker 3.08 0.98 9.67
Ex-smoker 2.13 0.90 5.04
Never smoked 1.00 – –
Previous anti-TNF treatment
Infliximab 0.74 0.35 1.53
Adalimumab 0.87 0.42 1.83
Any anti-TNF treatment 1.06 0.50 2.23
Disease phenotype at surgery
Penetrating, B3 1.08 0.47 2.46
25-OH vitamin D at baseline
Vitamin D, 50 nmol/L 1.00 – –
Vitamin D, >50 to 75 nmol/L 0.74 0.29 1.86
Vitamin D, >75 nmol/L 0.55 0.17 1.76
Calcium level at baseline
<2.2 mmol/L 1.40 0.58 3.36
PTH level at baseline
<2 pmol/L NA
Calprotectin level at week 26
0–50 mg/g 1.00 – –
50–250 mg/g 5.1 1.2 21.9
>250 mg/g 7.3 1.8 30.6
Ethnic background
Caucasian 1.63 0.56 4.71
Season of inclusion date
Autumn/winter 1.66 0.79 3.47
NA, not applicable; OR, odds ratio; PTH, parathyroid hormone; TNF, tumor
necrosis factor; 25-OH vitamin D, 25-hydroxyvitamin vitamin D.




















































































































928in part to the fact that the study patients often received
no treatment at all but “watchful-waiting” for 6 months
postoperatively. Because the patients usually were free
of symptoms, the motivation to adhere to the trial re-
quirements was suboptimal. Because of this higher loss
to follow-up rate, the targeted sample size was not
reached. However, in all analyses there was no signifi-
cant difference in outcome. Second, we treated all pa-
tients with 25,000 IU vitamin D irrespective of serum
vitamin D level. It could be argued that a treat-to-target
study design to reach serum 25-OH vitamin D levels
greater than 75 nmol/L would have been more optimal
because it recently was performed in a small clinical trial
in patients with active IBD.44 However, in our patient
cohort those levels were reached at fixed doses in every
patient. Nevertheless, a postoperative trial, in our
opinion, is an excellent model for truly investigating the
anti-inflammatory effect of, in this case, vitamin D,
because after resection the disease could be consideredFLA 5.6.0 DTD  YJCGH57247_proof as a “reset to zero,” thereby diminishing possible con-
founding factors as concomitant immunomodulating
medication and disease activity.
In conclusion, high-dose vitamin D treatment, reach-
ing adequate vitamin D levels 6 weeks after ileocolonic
resection, did not reduce endoscopic and clinical CD
recurrence.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2020.05.037.26 JReferences
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Figure 1. Patient flow
diagram.
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Supplementary Figure 2. Endoscopic and clinical odds ratio
(95% CI) of vitamin D (VitD) treatment in patient subgroups:
baseline levels of serum 25-hydroxy vitamin D, baseline cal-
cium (Ca) levels, baseline parathyroid hormone (PTH) levels,
ethnic background (Caucasian/other), and season of inclu-
sion (spring/summer vs autumn/winter). The P value refer to
the treatment by subgroup interaction in the logistic regres-
sion model.
FLA 5.6.0 DTD  YJCGH57247_proof  26 July 2020  4:55 am  ce DVC





















































































































Supplementary Table 1. Average Baseline Levels (SD) and Estimated Average Change Between Baseline and 26 Weeks (SE)
of Various Laboratory Parameters
Baseline Change at 26 weeks from baseline
Vitamin D, mean (SD) Placebo, mean (SD) Vitamin D, mean (SE) Placebo, mean (SE) P value
25-OH vitamin D, nmol/L 47.0 (25.9) 46.3 (24.1) 40.3 (5.32) 3.19 (4.13) <.0001
Calcium, mmol/L 2.28 (0.15) 2.27 (0.14) 0.04 (0.02) 0.07 (0.02) .31
PTH, pmol/L 4.78 (3.75) 3.81 (2.20) -0.22 (0.62) 1.29 (0.45) .042
Fecal calprotectin, mg/g 570 (404) 567 (400) -203 (54) -150 (54) .48
Serum albumin, g/L 37 (7) 36 (6) 6.3 (0.7) 6.6 (0.7) .73
Hemoglobin, mmol/L 7.4 (1.0) 7.1 (1.1) 0.9 (0.1) 0.7 (0.2) .41
CRP, mg/L 57.7 (62.1) 67.6 (75.8) -49.9 (8.0) -53.8 (8.8) .51
CRP, C-reactive protein; PTH, parathyroid hormone; 25-OH vitamin D, 25-hydroxyvitamin vitamin D.
Supplementary Table 2. CDAI Scores During The Trial
CDAI score Vitamin D Placebo
Baseline n ¼ 54 (%) n ¼ 53 (%)
0–50 5 (9.3) 4 (7.5)
50–150 18 (33.3) 26 (49.1)
150–200 13 (24.1) 8 (15.1)
200–220 1 (1.9) 1 (1.9)
>220 17 (31.5) 14 (26.4)
Week 6 n ¼ 60 (%) n ¼ 51 (%)
0–50 15 (25.0) 10 (19.6)
50–150 27 (45.0) 27 (52.9)
150–200 9 (15.0) 7 (13.7)
200–220 4 (6.7) 3 (5.9)
>220 5 (8.3) 4 (7.8)
Week 12 n ¼ 53 (%) n ¼ 55 (%)
0–50 17 (32.1) 16 (29.1)
50–150 22 (41.5) 31 (56.4)
150–200 10 (18.9) 2 (3.6)
200–220 1 (1.9) 0 (0.0)
>220 3 (5.7) 6 (10.9)
Week 26 n ¼ 54 (%) n ¼ 52 (%)
0–50 15 (27.8) 21 (40.4)
50–150 31 (57.4) 27 (51.9)
150–200 4 (7.4) 3 (5.8)
200–220 0 (0.0) 0 (0.0)
>220 4 (7.4) 1 (1.9)
CDAI, Crohn’s disease activity index.
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Supplementary Table 3. Average Baseline Levels (SD) and Estimated Average Change Between Baseline and 26 Weeks (SE)
of Various Questionnaire Parameters
Baseline Change at 26 weeks from baseline
Vitamin D, mean (SD) Placebo, mean (SD) Vitamin D, mean (SE) Placebo, mean (SE) P value
CDAI 172 (98) 158 (101) -62 (12) -82 (12) .24
EQ-5D Total 57 (18) 61 (15) 15.5 (2.3) 13.1 (2.4) .48
SF-36 PCS 36 (10) 36 (10) 10.9 (1.3) 11.4 (1.4) .77
MCS 42 (13) 41 (12) 6.3 (1.4) 5.0 (1.5) .53
IBDQ Bowel 48 (10) 48 (9) 4.6 (1.1) 7.2 (1.2) .12
Systemic 19 (7) 18 (6) 4.9 (0.7) 6.7 (0.8) .08
Social 21 (8) 22 (7) 8.3 (1.0) 7.9 (1.0) .73
Emotional 56 (16) 55 (13) 6.9 (1.4) 10.4 (1.5) .09
Total 147 (36) 146 (30) 24.9 (3.7) 31.1 (3.8) .25
CDAI, Crohn’s disease activity index; EQ-5D, EuroQol, 5-dimension questionnaire; IBDQ, Inflammatory Bowel Disease Questionnaire; MCS, mental component
summary; PCS, physical component summary; SF-36, 36-Item Short Form Health Survey.
FLA 5.6.0 DTD  YJCGH57247_proof  26 July 2020  4:55 am  ce DVC
- 2020 Vitamin D and CD 10.e5
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
